Arbutus Biopharma Corp. (NASDAQ:ABUS) was upgraded by equities research analysts at Chardan Capital from a “neutral” rating to a “buy” rating in a research note issued on Wednesday. The firm currently has a $4.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s price objective would indicate a potential upside of 50.94% from the stock’s current price.

Several other brokerages have also issued reports on ABUS. Wedbush reiterated an “outperform” rating and set a $20.00 price target (up from $13.00) on shares of Arbutus Biopharma Corp. in a report on Friday, August 5th. Leerink Swann lowered Arbutus Biopharma Corp. from an “outperform” rating to a “market perform” rating and set a $5.00 price target for the company. in a report on Friday, August 5th. Zacks Investment Research downgraded Arbutus Biopharma Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Finally, William Blair reissued an “outperform” rating on shares of Arbutus Biopharma Corp. in a research note on Sunday, August 21st. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $7.38.

Analyst Recommendations for Arbutus Biopharma Corp. (NASDAQ:ABUS)

Arbutus Biopharma Corp. (NASDAQ:ABUS) opened at 2.65 on Wednesday. The stock’s 50 day moving average price is $2.95 and its 200 day moving average price is $3.61. The stock’s market capitalization is $145.33 million. Arbutus Biopharma Corp. has a 1-year low of $2.45 and a 1-year high of $5.70.

COPYRIGHT VIOLATION WARNING: “Chardan Capital Upgrades Arbutus Biopharma Corp. (ABUS) to “Buy”” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States and international copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/30/chardan-capital-upgrades-arbutus-biopharma-corp-abus-to-buy.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Credit Suisse AG increased its position in shares of Arbutus Biopharma Corp. by 0.6% in the third quarter. Credit Suisse AG now owns 177,260 shares of the biopharmaceutical company’s stock valued at $610,000 after buying an additional 990 shares in the last quarter. AXA increased its position in shares of Arbutus Biopharma Corp. by 1.4% in the second quarter. AXA now owns 792,358 shares of the biopharmaceutical company’s stock valued at $2,757,000 after buying an additional 11,062 shares in the last quarter. KCG Holdings Inc. acquired a new position in shares of Arbutus Biopharma Corp. during the third quarter valued at approximately $102,000. Suffolk Capital Management LLC increased its position in shares of Arbutus Biopharma Corp. by 7.6% in the second quarter. Suffolk Capital Management LLC now owns 441,915 shares of the biopharmaceutical company’s stock valued at $1,538,000 after buying an additional 31,023 shares in the last quarter. Finally, K2 Principal Fund L.P. increased its position in shares of Arbutus Biopharma Corp. by 113.6% in the second quarter. K2 Principal Fund L.P. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 33,796 shares in the last quarter. 60.82% of the stock is currently owned by institutional investors.

Arbutus Biopharma Corp. Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

5 Day Chart for NASDAQ:ABUS

Receive News & Stock Ratings for Arbutus Biopharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp. and related stocks with our FREE daily email newsletter.